



**Grant Number:** 5U01CA033193-26

**Principal Investigator(s):**  
Vincent J Cogliano, PHD

**Project Title:** Evaluation of Carcinogenic Risks to Humans

Peter Boyle  
DIRECTOR, DIV OF ADMIN & FINANCE  
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER  
150, COURS ALBERT THOMAS  
69372 LYON CEDEX 08  
LYON CEDEX,  
FRANCE

**Award e-mailed to:** daf@iarc.fr

**Budget Period:** 09/12/2007 – 08/31/2008  
**Project Period:** 09/01/1985 – 08/31/2010

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$762,033 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to INTERNATIONAL AGENCY FOR RES ON CANCER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 & 6306 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release or other document that cites results from NIH grant-supported research must include an acknowledgment of NIH grant support and disclaimer such as "The project described was supported by Grant Number U01CA033193 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health."

Award recipients are strongly encouraged to submit to PubMed Central (PMC), upon acceptance for publication, an electronic version of peer-reviewed, original research publications, resulting from research supported in whole or in part, with direct costs from National Institutes of Health. The author's final manuscript is defined as the final version accepted for journal publication, and includes all modifications from the publishing peer review process. For additional information, please visit <http://publicaccess.nih.gov/>.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Galen Gregor  
Grants Management Officer  
NATIONAL CANCER INSTITUTE

Additional information follows



---

**SECTION I – AWARD DATA – 5U01CA033193-26****Award Calculation (U.S. Dollars)**

Salaries and Wages	\$372,476
Fringe Benefits	\$124,191
Travel Costs	\$2,015
Other Costs	\$194,592

Federal Direct Costs	\$693,274
Federal F&A Costs	\$90,126
Approved Budget	\$783,400
Federal Share	\$783,400
Less Unobligated Balance	\$21,367
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$762,033</b>

**AMOUNT OF THIS ACTION (FEDERAL SHARE) \$762,033**

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
26	\$762,033	\$762,033
27	(b)(5)	
28		

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**Fiscal Information:**

CFDA Number: 93.393  
EIN: 1900210016A1  
Document Number: UCA033193F  
Fiscal Year: 2007

IC	CAN	2007	2008	2009
CA	8423126	\$762,033	(b)(5)	

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**NIH Administrative Data:**

PCC: 9QCG3126 / OC: 414P

---

**SECTION II – PAYMENT/HOTLINE INFORMATION – 5U01CA033193-26**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

---

**SECTION III – TERMS AND CONDITIONS – 5U01CA033193-26**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- The restrictions on the expenditure of federal funds in appropriations acts to the extent those restrictions are pertinent to the award.
- 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at 'http://grants.nih.gov/grants/policy/awardconditions.htm' for certain references cited above.)

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

**Treatment of Program Income:  
Additional Costs**

---

**SECTION IV – CA Special Terms and Conditions – 5U01CA033193-26**

**INFORMATION** This award is issued as a Cooperative Agreement, a financial assistance mechanism which requires cooperation between the awardee and the National Cancer Institute (NCI). The following Terms of Cooperation include the Programmatic Responsibilities of the Grantees, the Nature of Assistance by NCI Staff, Collaborative Responsibilities, and Arbitration Procedures (Attachment 1).

These special Terms and Conditions of Award are in addition to and not in lieu of otherwise applicable OMB administrative guidelines, Federal Regulations, including HHS Grant Administration Regulations at 42 CFR Part 52, 45 CFR Parts 74 and 92, and other HHS, PHS, and NIH Grant Administration policy statements.

The following administrative terms also apply:

**RESTRICTION** This supplemental award provides \$48,550 (\$42,965 direct costs and \$5,585 associated facilities and administrative costs) to replace the support for the publication of IARC Monographs that was lost with the discontinuance of the support contract to TRI, as requested in the awardee's letter dated May 31, 2007. These funds are restricted and may not be expended for any other purpose without the written prior approval of the National Cancer Institute. Funds awarded are available for carryover for awards given carryover authority as reflected in section III of this award notice. However, the funds remain restricted for the purpose for which the supplement is awarded.

**INFORMATION** This non-competing award reflects an adjustment of the amount recommended on the previous Notice of Grant Award, per the NIH implementation of the FY 07 fiscal policy (See NIH Guide Notice NOT-OD-07-049 <http://grants.nih.gov/grants/guide/notice-files/NOT-OD-07-049.html> ). Future year recommended levels also have been adjusted consistent with the referenced Notice.

**INFORMATION** This award utilizes as an offset the unobligated balance from the -24 year financial status report.

**INFORMATION** This award includes funds for 12 months of support. The budget period start date has been delayed from 9/1/2007 to 9/12/2007 due to the NCI's late receipt of the year -24 Financial Status Report; however, the expiration date of the budget period remains unchanged (08/31/2008). Allowable preaward costs may be charged to this award in accordance with the conditions outlined in the NIH Grants Policy Statement (December 2003) and with institutional requirements for prior approval. The NIH GPS can be found on the internet at [http://grants2.nih.gov/grants/policy/nihgps\\_2003/](http://grants2.nih.gov/grants/policy/nihgps_2003/).

**INFORMATION** This award, including the budget and the budget period, has been discussed between Galen Gregor of the National Cancer Institute and Dr. Cogliano on 9/3/07.

**INFORMATION** In a continuing effort to provide exceptional customer service, the NCI Grants Administration Branch has set up a Feedback address on its web site (<http://www.nci.nih.gov/admin/gab/index.htm>). General concerns and issues related to NCI grants policies, procedures, and practices can be sent to the Customer Liaison using this feature. Specific questions or concerns related to this grant should be addressed to the Grants Management Specialist listed in the Terms of Award.

**STAFF CONTACTS**

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an

Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

**Grants Management Specialist:** Galen Gregor  
**Email:** gregorg@mail.nih.gov **Phone:** 301-496-1201

**Program Official:** Alan P. Poland  
**Email:** polanda@mail.nih.gov **Phone:** (301) 496-1625 **Fax:** (301) 496-1040

**SPREADSHEET SUMMARY**  
**GRANT NUMBER:** 5U01CA033193-26

**INSTITUTION:** INTERNATIONAL AGENCY FOR RES ON CANCER

<i>Budget</i>	<i>Year 26</i>	<i>Year 27</i>	<i>Year 28</i>
Salaries and Wages	\$372,476	(b)(5)	
Fringe Benefits	\$124,191		
Consultant Services			
Travel Costs	\$2,015		
Other Costs	\$194,592		
TOTAL FEDERAL DC	\$693,274		
TOTAL FEDERAL F&A	\$90,126		
TOTAL COST	\$762,033		

<i>Facilities and Administrative Costs</i>	<i>Year 26</i>	<i>Year 27</i>	<i>Year 28</i>
F&A Cost Rate 1	13%	(b)(5)	
F&A Cost Base 1	\$693,274		
F&A Costs 1	\$90,126		

5 UOI CA33193-

## Collaborative Terms of Award

### Nature of Collaboration with NCI Staff

NCI has certain responsibilities in terms of this cooperative agreement which involve assistance, information support, and scientific collaboration.

#### 1. Scientific Resource

Since the monographs on each chemical which appear in the volumes published by IARC are fundamentally an international information resource and data bank on carcinogenesis and evaluation of qualitative risk of chemicals to humans, NCI, in an assistance and cooperative role, provides information and data which assist IARC staff in the preparation of certain sections of the final monograph (Sections 1.1 to 2.3). Sections 3.1 to 4.3 are developed by the Working Groups which consist of international scientists who review all these documents at the time of the meetings (3 per year) in Lyon, France. The National Cancer Institute, through arrangements with a contractor will provide such assistance.

#### 2. Planning for Meetings of the Working Group

The IARC project is one of international support with NCI being the USA supporter for the monograph and the Information Bulletins on the Survey of Chemicals Being Tested for Carcinogenicity. This bulletin is a listing of chemicals being tested in laboratories throughout the world. Under the Cooperative Agreement, NCI:

- a. Makes suggestions to IARC on types of chemicals that should be evaluated at the three planned working group meetings per year held in Lyon, France.
- b. Makes suggestions and gives assistance to IARC as to USA resource people who should attend and participate in Working Group meetings. Personnel from regulatory agencies and trade associations should attend as observers.

#### 3. Program Involvement in Relation to Input from NCI

Under the section on scientific resources, reference was made to NCI input as to data on production, occurrence, analysis, and use of chemicals. NCI, also provides information relevant to carcinogenicity on chemicals tested in U.S. laboratories. These data are then incorporated in the Information Bulletin on the Survey of Chemicals Being Tested for Carcinogenicity.

5 UOI CA53193

#### Collaborative Terms of Award

In discussing certain phases of work that involve assistance and collaboration on the part of the NCI with IARC, reference was made to the essentiality of effective liaison and support. Participation by the NCI Program Director in the working group meetings in Lyon, France could be either as an observer or as a representative of NCI or as a full member of the working group in his personal capacity as a scientist.

#### 4. Reporting Requirements

NCI wishes to continue a semi-annual reporting requirement with scheduling or due dates for reports worked out by mutual arrangement between NCI staff and the IARC principal investigator. The volumes of monographs, supplements and survey bulletins are actually exhibits of achievements and accomplishments. Consequently, the semi-annual reports should dwell on planning, participation, selection of chemicals, problems of interfacing and cooperation and logistical matters. In addition, an annual report to be included in the required continuation applications should reflect that the project continues to conform to the purposes, objectives, and conditions of the award and has substantial programmatic involvement by NCI with the performer of the project.

#### 5. Publication and Distribution

One of the significant features of the IARC project in development of this international authoritative reference source is the publication and distribution, on a world-wide basis, of these volumes, including the supplements to the volumes listing Chemicals and Industrial Processes Associated with Cancer in Humans, as well as the Survey Bulletins.

The National Cancer Institute will receive approximately 400 copies of each volume published. The NCI distributes these copies to NCI staff, representatives of other agencies interested in environmental and occupational carcinogenesis, selected university scientists engaged in carcinogenesis research, public health organizations and medical libraries. Therefore, many organizations and scientists in the USA and abroad benefit from this program, which is partially supported by the National Cancer Institute.



Principal Investigator/Program Director (Last, First, Middle): Cogliano, Vincent James

DETAILED BUDGET FOR NEXT BUDGET PERIOD – DIRECT COSTS ONLY		FROM 09/01/2007		THROUGH 08/31/2008		GRANT NUMBER CA 33193	
PERSONNEL (Applicant organization only)		Months Devoted to Project			DOLLAR AMOUNT REQUESTED (omit cents)		
NAME	ROLE ON PROJECT	Cal. Mnths	Acad. Mnths	Sum. Mnths	SALARY REQUESTED	FRINGE BENEFITS	TOTALS
COGLIANO, V.J.	Principal Investigator	(b)(4), (b)(6)			0	0	0
SECRETAN, B.	Scientist				74,500	24,800	99,300
EL-GHISSASSI, F.	Scientist				73,700	24,600	98,300
P2 IARC Scientist *	Scientist	12			70,700	23,600	94,300
P2 IARC Scientist *	Scientist	12			64,900	21,600	86,500
LEZERE, M.	Publ. support	(b)(4), (b)(6)			39,600	13,200	52,800
EGRAZ, S.	Archivist				60,200	20,100	80,300
<b>SUBTOTALS</b> →					<b>383,600</b>	<b>127,900</b>	<b>511,500</b>
CONSULTANT COSTS							0
EQUIPMENT ( <i>Itemize</i> )							
SUPPLIES ( <i>Itemize by category</i> )							
TRAVEL One trip of PI to USA for a scientific meeting and to consult with NCI program officials							2,075
PATIENT CARE COSTS		INPATIENT					
		OUTPATIENT					
ALTERATIONS AND RENOVATIONS ( <i>Itemize by category</i> )							
OTHER EXPENSES ( <i>Itemize by category</i> ) See page 3							156,156
<b>SUBTOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD</b>							<b>\$ 669,731</b>
CONSORTIUM/CONTRACTUAL COSTS		DIRECT COSTS					
		FACILITIES AND ADMINISTRATIVE COSTS					
<b>TOTAL DIRECT COSTS FOR NEXT PROJECT PERIOD (<i>Item 8a, Face Page</i>)</b>							<b>\$ 669,731</b>



Principal Investigator/Program Director (Last, First, Middle): **Cogliano, Vincent James**

**BUDGET JUSTIFICATION**

GRANT NUMBER  
CA 33193

Provide a detailed budget justification for those line items and amounts that represent a significant change from that previously recommended. Use continuation pages if necessary.

**CONSULTANT :**

In order to remain within the limits of the recommended support for year 26 of the grant, and to ensure the funding for two working groups and printing of two volumes, no funds are requested for consultants. No honorarium will be paid to experts for the preparation of draft monographs and the editing work will be carried out by J. Mitchell, CIE staff member, covered by the IARC regular budget.

**OTHER :**

- Working groups (\$60,000 X 2)	\$120,000
- Printing of Monographs (\$13,000 X 2)	\$ 26,000
- Reprint requests	\$ 2,156
- Books, journals and reproduction costs	\$ 8,000
	-----
	\$156,156

**\* PERSONNEL :**

The 2 P2 IARC Scientist posts are currently occupied by Dr Bouvard V. and Dr Altieri A.

**CURRENT BUDGET PERIOD**

FROM  
09/01/2006

THROUGH  
08/31/2007

Explain any estimated unobligated balance (including prior year carryover) that is greater than 25% of the current year's total budget.

	Total estimated expenditure	Estimated unobligated balance
	-----	-----
DIRECT COSTS	\$650,226	\$0
INDIRECT COSTS	\$ 84,529	\$0
	-----	
<b>TOTAL COSTS</b>	<b>\$734,755</b>	<b>\$0</b>

Principal Investigator/Program Director (Last, First, Middle): Cogliano, Vincent James

Other Active Support

(b)(4), (b)(6)

01/01/07-12/31/07

\$71,300

(b)(4) %

The IARC Monographs 2007

No overlap with the NCI cooperative agreement. Funds used to support the 3<sup>rd</sup> Monographs meeting each year and scientific or advisory meetings relevant to the Monographs Programme.

Principal Investigator/Program Director (Last, First, Middle): **Cogliano, Vincent James**

<b>PROGRESS REPORT SUMMARY</b>	GRANT NUMBER 2U01 CA033193	
	PERIOD COVERED BY THIS REPORT	
PRINCIPAL INVESTIGATOR OR PROGRAM DIRECTOR Cogliano, Vincent James	FROM 09/01/2006	THROUGH 08/31/2007
APPLICANT ORGANIZATION International Agency for Research on Cancer		
TITLE OF PROJECT (Repeat title shown in Item 1 on first page) Evaluation of Carcinogenic Risks to Humans		
A. Human Subjects (Complete Item 6 on the Face Page)		
Involvement of Human Subjects	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
B. Vertebrate Animals (Complete Item 7 on the Face Page)		
Use of Vertebrate Animals	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
C. Select Agent Research	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
D. Multiple PI Leadership Plan	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change

SEE PHS 2590 INSTRUCTIONS.

**WOMEN AND MINORITY INCLUSION:** See PHS 398 Instructions. Use Inclusion Enrollment Report Format Page and, if necessary, Targeted/Planned Enrollment Format Page.

a. Specific Aims. [unchanged from original application] The aim of the IARC Monographs is to critically review and evaluate the published scientific evidence on carcinogenic hazards to which humans are exposed. These include chemicals, complex mixtures, occupational exposures, physical and biological agents, and lifestyle factors. International, interdisciplinary Working Groups write the critical reviews and develop the evaluations.

b. Studies and Results. During the past reporting year, IARC convened Working Groups to develop three new volumes of IARC Monographs. Topics for these volumes had been recommended as high priorities by IARC Monographs Advisory Groups in February 2003 and December 2004. [NCI funding supported development of two of the three volumes.]

Volume 95: Household solid fuel combustion and high-temperature frying.

About half the world's population, mostly in low- and medium-resource countries, use solid fuels (primarily wood and coal) for cooking and heating. WHO has identified indoor smoke from combustion of solid fuels as one of the top 10 risks in terms of the global burden of disease. Women and young children especially may be exposed to high levels of indoor smoke for most of their day.

Occupational exposure to coal combustion products has long been known to cause lung cancer, and now many studies, mostly from China, demonstrate similar effects from household use of coal. Biomass fuel (primarily wood) is used in many more households than coal, but its adverse health effects have not been as well studied. The available studies suggest that exposure to wood smoke is associated with an increased risk of lung cancer. Stir-frying, deep-frying, and pan-frying are practiced worldwide and are widespread in China. The available studies suggest that these types of high-temperature frying are associated with an increased risk of lung cancer.

Principal Investigator/Program Director (Last, First, Middle): Cogliano, Vincent James

A Working Group of 19 scientists from 8 countries met in October 2006 to critically review the pertinent scientific literature and develop the following evaluations.

Indoor emissions from household combustion of coal	<i>Carcinogenic to humans (Group 1)</i>
Indoor emissions from household combustion of biomass fuel (primarily wood)	<i>Probably carcinogenic (Group 2A)</i>
Emissions from high-temperature frying	<i>Probably carcinogenic (Group 2A)</i>

**Volume 96: Alcoholic beverage consumption and ethyl carbamate (urethane).**

Worldwide, nearly 2 billion adults are regular consumers of alcoholic beverages, with an average daily consumption of 13 g of ethanol (about one drink). Although moderate alcohol consumption has some health benefits, WHO has identified alcohol consumption as one of the top 10 risks in terms of the global burden of disease.

Alcoholic beverages have long been known to cause cancer of the oral cavity, pharynx, larynx, oesophagus, and liver. This new evaluation added breast cancer and colorectal cancer, two of the most common cancers worldwide, to the list of cancers causally related to alcohol consumption. This suggests that the proportion of cancers attributable to alcohol consumption is higher than was previously estimated. Because these associations were generally noted with different types of alcoholic beverage, and in view of the carcinogenicity of ethanol in experimental animals, some of these risks can be attributed to ethanol itself. There was also substantial mechanistic evidence in humans to indicate that acetaldehyde derived from the metabolism of ethanol in alcoholic beverages contributes to causing malignant oesophageal tumours.

A Working Group of 26 scientists from 15 countries met in February 2007 to critically review the pertinent scientific literature and develop the following evaluations.

Alcoholic beverages	<i>Carcinogenic to humans (Group 1)</i>
Ethanol in alcoholic beverages	<i>Carcinogenic to humans (Group 1)</i>
Ethyl carbamate (urethane)	<i>Probably carcinogenic (Group 2A)</i>

**Volume 97: 1,3-Butadiene, ethylene oxide, and vinyl halides (vinyl fluoride, vinyl chloride, vinyl bromide).**

As significant new data become available on an agent for which a *Monograph* exists, a reevaluation may be made. 1,3-Butadiene narrowly missed being classified in Group 1 during its previous evaluation; ethylene oxide was the first agent classified in Group 1 on the basis of strong mechanistic evidence in exposed humans, and vinyl chloride has been suspected of causing other human cancers in addition to angiosarcomas. In the time since the previous evaluations of these agents, significant new data have become available.

A working group of 21 scientists from 8 countries met in June 2007 to critically review the pertinent scientific literature and develop the following evaluations.

1,3-Butadiene	<i>Carcinogenic to humans (Group 1)</i>
Ethylene oxide	<i>Carcinogenic to humans (Group 1)</i>
Vinyl chloride	<i>Carcinogenic to humans (Group 1)</i>
Vinyl fluoride	<i>Probably carcinogenic (Group 2A)</i>
Vinyl bromide	<i>Probably carcinogenic (Group 2A)</i>

Principal Investigator/Program Director (Last, First, Middle): Cogliano, Vincent James

c. **Significance.** More than 400 carcinogenic or potentially carcinogenic agents have been identified among the approximately 900 agents evaluated in the first 97 volumes of *IARC Monographs*. National and international health agencies use the *IARC Monographs* as a source of information on potential carcinogens and as scientific support for their actions to reduce exposure to potential carcinogens. The *IARC Monographs* also are a resource to the scientific community for information on agents suspected of causing cancer.

d. **Plans.** During the period from September 2007 through August 2008, IARC will convene two more expert Working Groups to evaluate information on high-priority potentially carcinogenic agents. [NCI funding will support these two Working Groups.]

**Volume 98: Fire-fighting, painting, and shift work (2-9 October 2007).**

**Volume 99: Some industrial and cosmetic dyes, and related exposures (5-12 February 2008).**

Information on these meetings is available on the *Monographs* programme website, <http://monographs.iarc.fr/>.

In addition, the *Monographs* programme is planning to convene an Advisory Group in June 2008 to recommend agents that warrant high priority for consideration in future *IARC Monographs*. This Advisory Group will also review the plans and progress in the development of Volume 100, which will be a review of the human carcinogens identified to date. Six meetings will be scheduled between September 2008 and July 2009 to prepare *Monographs* for the approximately 100 agents that have been classified in Group 1 by the *IARC Monographs* programme. [NCI funding will not be used to support this Advisory Group meeting.]

#### e. Publications

Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Cogliano V and the WHO International Agency for Research on Cancer Monograph Working Group (2007). Carcinogenicity of alcoholic beverages. *Lancet Oncol.*, 8, 292-293

Grosse Y et al., 1,3-Butadiene, ethylene oxide and vinyl halides. *Lancet Oncol.* (in prep.)

IARC (2006) *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 86, Cobalt in hard-metals and cobalt sulfate, gallium arsenide, indium phosphide and vanadium pentoxide. Geneva, WHO Press

IARC (2006) *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 87, Lead and lead compounds. Geneva, WHO Press

IARC (2006). *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 88, Formaldehyde, 2-butoxyethanol and propylene glycol mono-t-butyl ether. Geneva, WHO Press

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 89, Smokeless tobacco and some related nitrosamines. Geneva, WHO Press (in prep.)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 90, Human papillomaviruses. Geneva, WHO Press (in prep.)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 91, Oestrogen-progestogen replacement therapy and oral contraceptives. Geneva, WHO Press (in prep.)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 92, Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. Geneva, WHO Press (in prep.)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 93, Carbon black, titanium. Geneva, WHO Press (in prep.)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 94, Ingested nitrates and nitrites and cyanobacterial peptide toxins. Geneva, WHO Press (in prep.)

Principal Investigator/Program Director (Last, First, Middle): Cogliano, Vincent James

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 95, Indoor air pollution from household cooking and heating: solid-fuel use and high-temperature frying. Geneva, WHO Press (in prep.)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 96, Alcoholic beverages and ethyl carbamate . Geneva, WHO Press (in prep.)

IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, Vol. 97, 1,3-Butadiene, ethylene oxide and vinyl halides (vinyl fluoride, vinyl chloride and vinyl bromide). Geneva, WHO Press (in prep.)

Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Cogliano V, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group (2006). Carcinogenicity of household solid fuel combustion and of high-temperature frying. *Lancet Oncol.* 7, 977-978

f. **Project-Generated Resources.** None.

Principal Investigator/Program Director (Last, first, middle): Cogliano, Vincent James

GRANT NUMBER  
CA033193

### CHECKLIST

#### 1. PROGRAM INCOME (See instructions.)

All applications must indicate whether program income is anticipated during the period(s) for which grant support is requested. If program income is anticipated, use the format below to reflect the amount and source(s).

Budget Period	Anticipated Amount	Source(s)

#### 2. ASSURANCES/CERTIFICATIONS (See instructions.)

In signing the application Face Page, the authorized organizational representative agrees to comply with the following policies, assurances and/or certifications when applicable. Descriptions of individual assurances/certifications are provided in Part III of the PHS 398. If unable to certify compliance, where applicable, provide an explanation and place it after this page.

• Human Subjects Research • Research Using Human Embryonic Stem Cells • Research on Transplantation of Human Fetal Tissue • Women and Minority Inclusion Policy • Inclusion of Children Policy • Vertebrate Animals

• Debarment and Suspension • Drug- Free Workplace (applicable to new [Type 1] or revised/resubmission [Type 1] applications only) • Lobbying • Non-Delinquency on Federal Debt • Research Misconduct • Civil Rights (Form HHS 441 or HHS 690) • Handicapped Individuals (Form HHS 641 or HHS 690) • Sex Discrimination (Form HHS 639-A or HHS 690) • Age Discrimination (Form HHS 680 or HHS 690) • Recombinant DNA Research, Including Human Gene Transfer Research • Financial Conflict of Interest (except Phase I SBIR/STTR) • Prohibited Research • Select Agent Research • PI Assurance • STTR ONLY: Certification of Research Institution Participation.

#### 3. FACILITIES AND ADMINISTRATIVE (F&A) COSTS

Indicate the applicant organization's most recent F&A cost rate established with the appropriate DHHS Regional Office, or, in the case of for-profit organizations, the rate established with the appropriate PHS Agency Cost Advisory Office.

F&A costs will *not* be paid on construction grants, grants to Federal organizations, grants to individuals, and conference grants. Follow any additional instructions provided for Research Career Awards, Institutional National Research Service Awards, Small Business Innovation Research/Small Business Technology Transfer Grants, foreign grants, and specialized grant applications.

DHHS Agreement dated: \_\_\_\_\_  No Facilities and Administrative Costs Requested.

No DHHS Agreement, but rate established with J.W. Berry, Accountant, DHHS Date 10/18/1983

#### CALCULATION\*

Entire proposed budget period: Amount of base \$ 669,731 x Rate applied 13.00 % = F&A costs \$ 87,065

Add to total direct costs from Form Page 2 and enter new total on Face Page, Item 8b.

\*Check appropriate box(es):

Salary and wages base  Modified total direct cost base  Other base (Explain)

Off-site, other special rate, or more than one rate involved (Explain)

Explanation (Attach separate sheet, if necessary.):

Rate applied to total direct costs

Principal Investigator/Program Director (Last, First, Middle): **Cogliano, Vincent James**

**KEY PERSONNEL REPORT**

GRANT NUMBER  
CA033193

Place this form at the end of the signed original copy of the application. Do not duplicate.

**All Key Personnel for the Current Budget Period (do not include Other Significant Contributors)**

Name	Degree(s)	SSN (last 4 digits)	Role on Project (e.g. PI, Res. Assoc.)	Date of Birth (MM/DD/YY)	Months Devoted to Project		
					Cal	Acad	Sum
VJ Cogliano	PhD	(b)(6)	PI	(b)(6)	(b)(4), (b)(6)		
R Baam	PhD	N/A	Scientist				
F El Ghissassi	PhD	N/A	Scientist				
Y Grosse	PhD	N/A	Scientist				
B Secretan	PhD	N/A	Scientist				
K Straif	MD, PhD	N/A	Scientist				
P2 IARC Scientist	PhD	N/A	Scientist		12		
P2 IARC Scientist	PhD	N/A	Scientist		12		